NCT03229746View on ClinicalTrials.gov

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Hydroxychloroquine

200mg twice daily orally for at least 12 weeks

DRUG

vincristine

1mg intravenous weekly for 4 weeks

DRUG

azathioprine

dose 100mg daily for at least 3 weeks

Trial Locations (1)

Unknown

Assiut university hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03229746 - Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter